Immunotherapy Focused NextCure Updates Its Filing for $93 Million IPO

Immunotherapy Focused NextCure Updates Its Filing for $93 Million IPO

Source: 
CP Wire
snippet: 

Clinical-stage biopharmaceutical company, NextCure, has updated its filing for an IPO to raise up to $93 million. The company has applied to trade on NASDAQ under the symbol, "NXTC”.